Detecting Liver Cancer Early with Blood Tests
Author Information
Author(s): Ren Qingqi, Li Shiyong, Zhong Guolin, Li Yunfei, Huang Dao‐Ling, Zhang Liangliang, Feng Yumin, Long Guanghui, Mao Mao
Primary Institution: Peking University Shenzhen Hospital
Hypothesis
Can circulating tumor DNA and alpha-fetoprotein effectively detect minimal residual disease in liver cancer patients after surgery?
Conclusion
The study shows that a blood test combining ctDNA and AFP can predict the risk of liver cancer recurrence after surgery.
Supporting Evidence
- 87.5% of patients had detectable cancer signals before surgery.
- Patients with undetectable cancer signals post-surgery had a 100% survival rate.
- MRD-positive patients had a significantly lower overall survival compared to MRD-negative patients.
Takeaway
Doctors can use a blood test to find tiny amounts of cancer left after surgery, which helps them know who might get sick again.
Methodology
The study used a multi-omics assay to analyze blood samples from liver cancer patients before and after surgery.
Potential Biases
Potential bias due to the small sample size and specific patient population.
Limitations
The sample size was small and primarily focused on HBV-positive patients.
Participant Demographics
{"median_age":52,"gender_distribution":{"male":27,"female":5},"cancer_stage":{"stage_I":21,"stage_II":4,"stage_III":7},"HBV_infection":29}
Statistical Information
P-Value
p<0.01
Confidence Interval
95% CI 1.33–24.20
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website